繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Galecto启动抗MutCALR管道候选药物的临床开发

2026-01-12 21:17

  • DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administration
  • Recent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical Officer
  • Pipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026
  • Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。